PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Discover the newly identified proteins to predict ICANS, improving the safety of CAR-T cell therapy by identifying high-risk ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs.

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review ...

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from Buy to Neutral. Analyst Price Forecast Suggests 207.54% Upside As ...